PL3471760T3 - Nowe formulacje immunogenne zawierające adiuwanty liniowego lub rozgałęzionego polimeru kwasu akrylowego - Google Patents
Nowe formulacje immunogenne zawierające adiuwanty liniowego lub rozgałęzionego polimeru kwasu akrylowegoInfo
- Publication number
- PL3471760T3 PL3471760T3 PL17736804.0T PL17736804T PL3471760T3 PL 3471760 T3 PL3471760 T3 PL 3471760T3 PL 17736804 T PL17736804 T PL 17736804T PL 3471760 T3 PL3471760 T3 PL 3471760T3
- Authority
- PL
- Poland
- Prior art keywords
- linear
- polyacrylic acid
- acid polymer
- immunogenic formulations
- novel immunogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F6/00—Post-polymerisation treatments
- C08F6/001—Removal of residual monomers by physical means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/04—Acids; Metal salts or ammonium salts thereof
- C08F120/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351492P | 2016-06-17 | 2016-06-17 | |
| PCT/US2017/037745 WO2017218819A1 (en) | 2016-06-17 | 2017-06-15 | Novel immunogenic formulations comprising linear or branched polyacrylic acid polymer adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3471760T3 true PL3471760T3 (pl) | 2025-04-22 |
Family
ID=59295306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17736804.0T PL3471760T3 (pl) | 2016-06-17 | 2017-06-15 | Nowe formulacje immunogenne zawierające adiuwanty liniowego lub rozgałęzionego polimeru kwasu akrylowego |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11554170B2 (pl) |
| EP (1) | EP3471760B1 (pl) |
| JP (1) | JP7018941B2 (pl) |
| KR (1) | KR102724939B1 (pl) |
| CN (1) | CN109475615B (pl) |
| AU (1) | AU2017286727B2 (pl) |
| BR (1) | BR112018076015A8 (pl) |
| CA (1) | CA3027877A1 (pl) |
| DK (1) | DK3471760T3 (pl) |
| ES (1) | ES3006465T3 (pl) |
| FI (1) | FI3471760T3 (pl) |
| HR (1) | HRP20250077T1 (pl) |
| HU (1) | HUE070052T2 (pl) |
| LT (1) | LT3471760T (pl) |
| MX (1) | MX395520B (pl) |
| PL (1) | PL3471760T3 (pl) |
| PT (1) | PT3471760T (pl) |
| RS (1) | RS66469B1 (pl) |
| SI (1) | SI3471760T1 (pl) |
| WO (1) | WO2017218819A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL273120B2 (en) * | 2017-09-13 | 2023-10-01 | Sanofi Pasteur | A compound that induces an immune response to cytomegalovirus |
| CA3095174A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic ospa polypeptides |
| MX2020010199A (es) | 2018-04-03 | 2021-01-08 | Sanofi Sa | Polipeptidos antigenicos del virus sincitial respiratorio. |
| EP3773703A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic influenza-ferritin polypeptides |
| WO2019195316A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Ferritin proteins |
| WO2019195314A2 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic epstein barr virus polypeptides |
| CN109134724A (zh) * | 2018-07-24 | 2019-01-04 | 石家庄哈顿生物技术有限公司 | 一种动物疫苗用聚丙烯酸类聚合物佐剂的研制方法 |
| BR112021013241A2 (pt) * | 2019-01-04 | 2021-09-14 | Boehringer Ingelheim Animal Health USA Inc. | Cepas atenuadas de bordetella bronchiseptica, vacinas orais contendo as cepas atenuadas e métodos de preparação e uso das mesmas |
| JP7657727B2 (ja) | 2019-04-02 | 2025-04-07 | サノフイ | 抗原性多量体呼吸器合胞体ウイルスポリペプチド |
| CN113444743A (zh) * | 2021-06-22 | 2021-09-28 | 贵州大学 | 含佐剂基因的羊支原体肺炎二价核酸疫苗的构建方法 |
| WO2023120535A1 (ja) * | 2021-12-20 | 2023-06-29 | 東興薬品工業株式会社 | ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用 |
| WO2025005260A1 (ja) * | 2023-06-28 | 2025-01-02 | 国立感染症研究所長が代表する日本国 | ワクチンアジュバント組成物およびその使用 |
| US20250281605A1 (en) | 2024-03-08 | 2025-09-11 | Sanofi | Antigenic Epstein Barr Virus Polypeptides |
| WO2026008743A1 (en) | 2024-07-02 | 2026-01-08 | Sanofi Pasteur Inc. | Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3790665A (en) | 1968-02-23 | 1974-02-05 | Haver Lockhart Labor Inc | Injectable adjuvant,method of preparing same and compositions including such adjuvant |
| US3919411A (en) | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| NZ215069A (en) | 1985-03-01 | 1988-06-30 | Reckitt & Colmann Prod Ltd | Pharmaceutical composition with histamine h 2 -receptor antagonist |
| JP2607712B2 (ja) | 1988-01-29 | 1997-05-07 | カイロン コーポレイション | 組換えｃｍｖ中和タンパク |
| DE69233158T2 (de) | 1991-03-07 | 2004-05-13 | Connaught Technology Corp., Greenville | Gentechnologisch hergestellter stamm für impfstoffe |
| US5846805A (en) | 1991-08-26 | 1998-12-08 | Boehringer Ingelheim Animal Health, Inc. | Culture of swine infertility and respiratory syndrome virus in simian cells |
| US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
| US5695766A (en) | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
| PL178609B1 (pl) | 1993-02-08 | 2000-05-31 | Bayer Ag | Izolat wirusa zespołu reprodukcyjnego i oddechowego świń zwanego PRRSV, sposób namnażania izolatu PRRSV, klon linii komórkowej, hodowla tkankowa zawierająca izolat PRRSV, szczepionka efektywna w ochronie świń przeciw PRRSV oraz sposób wytwarzania szczepionki efektywnej w ochronie świń przeciw PRRSV |
| FR2723740B1 (fr) | 1994-08-16 | 1996-11-08 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
| BE1008977A5 (fr) | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
| US5866401A (en) | 1996-03-01 | 1999-02-02 | Schering Corporation | Porcine reproductive and respiratory syndrome vaccine |
| GB9622159D0 (en) * | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
| US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| FR2776928B1 (fr) | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
| TWI224107B (en) | 1998-10-22 | 2004-11-21 | Pfizer Prod Inc | Novel proteins from actinobacillus pleuropneumoniae |
| UA84024C2 (ru) | 2003-07-24 | 2008-09-10 | Мериал Лимитед | Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде" |
| GB0400264D0 (en) | 2004-01-07 | 2004-02-11 | Polytherics Ltd | Complexes |
| US7425336B2 (en) | 2005-08-25 | 2008-09-16 | Mevial Limited | Canine influenza vaccines |
| GB0805356D0 (en) | 2008-03-25 | 2008-04-30 | Isis Innovation | Vaccine adjuvant composition |
| CN102858883B (zh) * | 2010-02-12 | 2015-09-09 | 罗地亚管理公司 | 流变改进剂组合物及其使用方法 |
| AU2013204906B2 (en) * | 2012-03-12 | 2016-01-07 | Advanced Bioadjuvants, Llc | Adjuvant and vaccine compositions |
-
2017
- 2017-06-15 PL PL17736804.0T patent/PL3471760T3/pl unknown
- 2017-06-15 SI SI201731579T patent/SI3471760T1/sl unknown
- 2017-06-15 JP JP2019518171A patent/JP7018941B2/ja active Active
- 2017-06-15 CN CN201780044245.6A patent/CN109475615B/zh active Active
- 2017-06-15 AU AU2017286727A patent/AU2017286727B2/en active Active
- 2017-06-15 WO PCT/US2017/037745 patent/WO2017218819A1/en not_active Ceased
- 2017-06-15 MX MX2018015787A patent/MX395520B/es unknown
- 2017-06-15 RS RS20250057A patent/RS66469B1/sr unknown
- 2017-06-15 FI FIEP17736804.0T patent/FI3471760T3/fi active
- 2017-06-15 EP EP17736804.0A patent/EP3471760B1/en active Active
- 2017-06-15 BR BR112018076015A patent/BR112018076015A8/pt active Search and Examination
- 2017-06-15 HR HRP20250077TT patent/HRP20250077T1/hr unknown
- 2017-06-15 CA CA3027877A patent/CA3027877A1/en active Pending
- 2017-06-15 ES ES17736804T patent/ES3006465T3/es active Active
- 2017-06-15 LT LTEPPCT/US2017/037745T patent/LT3471760T/lt unknown
- 2017-06-15 PT PT177368040T patent/PT3471760T/pt unknown
- 2017-06-15 KR KR1020197001525A patent/KR102724939B1/ko active Active
- 2017-06-15 HU HUE17736804A patent/HUE070052T2/hu unknown
- 2017-06-15 US US15/624,405 patent/US11554170B2/en active Active
- 2017-06-15 DK DK17736804.0T patent/DK3471760T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017286727A1 (en) | 2019-01-31 |
| KR102724939B1 (ko) | 2024-11-01 |
| DK3471760T3 (da) | 2025-01-27 |
| KR20190044052A (ko) | 2019-04-29 |
| AU2017286727B2 (en) | 2024-02-08 |
| US20170360923A1 (en) | 2017-12-21 |
| ES3006465T3 (en) | 2025-03-18 |
| PT3471760T (pt) | 2025-01-20 |
| HRP20250077T1 (hr) | 2025-03-28 |
| MX2018015787A (es) | 2019-04-22 |
| SI3471760T1 (sl) | 2025-06-30 |
| BR112018076015A8 (pt) | 2022-06-28 |
| MX395520B (es) | 2025-03-26 |
| FI3471760T3 (fi) | 2025-01-27 |
| CN109475615B (zh) | 2023-04-07 |
| RS66469B1 (sr) | 2025-03-31 |
| CN109475615A (zh) | 2019-03-15 |
| EP3471760B1 (en) | 2024-11-06 |
| CA3027877A1 (en) | 2017-12-21 |
| EP3471760A1 (en) | 2019-04-24 |
| BR112018076015A2 (pt) | 2019-03-26 |
| HUE070052T2 (hu) | 2025-05-28 |
| WO2017218819A1 (en) | 2017-12-21 |
| US11554170B2 (en) | 2023-01-17 |
| LT3471760T (lt) | 2025-02-25 |
| JP7018941B2 (ja) | 2022-02-14 |
| JP2019524873A (ja) | 2019-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3471760T3 (pl) | Nowe formulacje immunogenne zawierające adiuwanty liniowego lub rozgałęzionego polimeru kwasu akrylowego | |
| IL257800A (en) | Immune compositions with improved stability and immunogenicity | |
| PL3582627T3 (pl) | Formulacje stabilne podczas przechowywania | |
| PL3167032T3 (pl) | Trwałe przy przechowywaniu kompozycje zawierające polimery uwalniające brud | |
| IL265609A (en) | New formulations | |
| PL3603619T3 (pl) | Preparat adjuwantu szczepionkowego | |
| IL263624B (en) | HIV vaccine formulation | |
| GB201711635D0 (en) | Immunogenic composition | |
| ZA201902563B (en) | Expec glycoconjugate vaccine formulations | |
| GB201610599D0 (en) | Immunogenic Composition | |
| GB201607918D0 (en) | Novel formulations | |
| IL271603A (en) | Immunogenic preparations | |
| IL251120B (en) | Immunogenic/therapeutic glycoside preparations and their uses | |
| ZA201905379B (en) | 1-amino-1-cyclopropanecaboxylic acid formulations | |
| EP3397277C0 (en) | IMMUNOGENIC COMPOSITION | |
| GB201711637D0 (en) | Immunogenic composition | |
| IL274149A (en) | Sustained release formulations for intra-articular applications | |
| SG11202103389WA (en) | Immunogenic compositions | |
| GB201614485D0 (en) | Immunogenic composition | |
| GB201604755D0 (en) | Immunogenic compositions | |
| GB201918963D0 (en) | Polymeric nanoparticles as vaccine adjuvants | |
| ZA201903372B (en) | Adjuvants for agrochemical formulations | |
| GB201714183D0 (en) | Universally immunogenic formulations | |
| GB201501153D0 (en) | Immunogenic formulations | |
| GB201405857D0 (en) | Immunogenic formulations |